Use of oxazolidinones (linezolid or tedizolid) for the treatment of breast infections. A case series from a tertiary referral hospital
Infection · 2024
DOI: 10.1007/s15010-024-02269-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection, 2024. Verfasst von Cristina Kirkegaard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Ca…. Hauptthemen laut MEDLINE: Tertiary Care Centers, Oxazolidinones, Linezolid, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Mastitis is mainly caused by Gram-positive bacteria and usually involves treatment with beta-lactam antibiotics and clindamycin. Oxazolidinones show good results in the treatment of skin and soft tissue infections (SSTIs) due to its pharmacokinetic characteristics. We aimed to describe clinical characteristics and outcomes of patients who received oxazolidinones for the treatment of SSTIs of the mammary tissue. METHODS: Retrospective single-centre study of patients with a diagnosis of breast infection who received treatment with oxazolidinones as initial or salvage therapy between September 2016 and November 2022. Patients were identified through the pharmacy database. The primary outcome was clinical cure. RESULTS: Twenty-nine patients received oxazolidinones: 27 received linezolid and 2 tedizolid. Median age was 41 years (IQR 31.0-56.5) and 28 patients were female. Ten patients (35%) had a history of breast cancer, while three (10%) had an immunosuppressive condition. Microbiological isolation was obtained in 24 individuals (83%). Predominant isolations were methicillin-resistant Staphylococcus aureus (8, 28%) and methicillin-susceptible S. aureus (7, 24%). Twenty-four patients (83%) received oxazolidinones as a salvage therapy, with a median duration of 14 days (IQR 10-17). Clinical cure was achieved in 24 patients (83%), while 4 relapsed after a median of 15 days (IQR 4-34). One was lost to follow-up. Three patients (10%) were taking selective serotonin reuptake inhibitors, and one of them concurrently received linezolid for 4 days with no adverse events recorded. Cytopenia during treatment was observed in 2/12 individuals. Oxazolidinones allowed hospital discharge in 11/13 hospitalized patients. CONCLUSIONS: Oxazolidinones could be considered as an alternative for treating breast infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari. Passeig de la Vall d'Hebron 119-129, 08035, Barcelon…
- Pharmacy Service, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Campus Hospitalari. Passeig de la Vall d'Hebron 119-129, 08035, Barcelona, Spain.
- Department of Breast Surgical Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Campus Hospitalari, Passeig de la Vall d'Hebron 119-129, 08035, Barcelona, Spain.
- Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. nuria.fernandezhidalgo@vallhebron.cat.
- CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. nuria.fernandezhidalgo@vallhebron.cat.
Zitieren
APA
Kirkegaard, C., Parramón-Teixidó, C. J., Morales-Comas, C., Clemente Bautista, S., Rivero Deniz, J., & Fernández-Hidalgo, N. (2024). Use of oxazolidinones (linezolid or tedizolid) for the treatment of breast infections. A case series from a tertiary referral hospital. Infection. https://doi.org/10.1007/s15010-024-02269-y
Vancouver
Kirkegaard C, Parramón-Teixidó CJ, Morales-Comas C, Clemente Bautista S, Rivero Deniz J, Fernández-Hidalgo N. Use of oxazolidinones (linezolid or tedizolid) for the treatment of breast infections. A case series from a tertiary referral hospital. Infection. 2024. doi:10.1007/s15010-024-02269-y
BibTeX
@article{Kirkegaard2024,
author = {Kirkegaard, Cristina and Parramón-Teixidó, Carlos Javier and Morales-Comas, Clara and Clemente Bautista, Susana and Rivero Deniz, Joaquín and Fernández-Hidalgo, Nuria},
title = {Use of oxazolidinones (linezolid or tedizolid) for the treatment of breast infections. A case series from a tertiary referral hospital},
journal = {Infection},
year = {2024},
doi = {10.1007/s15010-024-02269-y}
}
EUVIMED